Document Detail

Pregnancy under treatment of imatinib and successful labor in a patient with chronic myelogenous leukemia (CML). Outcome of discontinuation of imatinib therapy after achieving a molecular remission.
MedLine Citation:
PMID:  15978950     Owner:  NLM     Status:  MEDLINE    
Because of the teratogenicity data in rats, it is recommended that women treated with imatinib should be aware of the potential teratogenicity of imatinib and effective contraception should be used during imatinib therapy to prevent pregnancy. We describe successful pregnancy and delivery, without any congenital anomaly, in a patient with CML under treatment of imatinib. The fetus had been exposed to imatinib for 8 weeks. The patient remained off treatment during gestation and cytogenetic relapse of CML (5 months after discontinuation of imatinib therapy) developed at seventh month of gestation.
Ridvan Ali; Fahir Ozkalemkaş; Tülay Ozçelik; Vildan Ozkocaman; Ulkü Ozan; Yalçin Kimya; Nilgün Köksal; Tuna Gülten; Tahsin Yakut; Ahmet Tunali
Publication Detail:
Type:  Case Reports; Journal Article     Date:  2005-02-16
Journal Detail:
Title:  Leukemia research     Volume:  29     ISSN:  0145-2126     ISO Abbreviation:  Leuk. Res.     Publication Date:  2005 Aug 
Date Detail:
Created Date:  2005-06-27     Completed Date:  2005-08-12     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7706787     Medline TA:  Leuk Res     Country:  England    
Other Details:
Languages:  eng     Pagination:  971-3     Citation Subset:  IM    
Division of Hematology, Department of Internal Medicine, Uludag University School of Medicine, Bursa, Turkey.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / adverse effects,  therapeutic use*
Infant, Newborn
Labor, Induced*
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy*
Piperazines / adverse effects,  therapeutic use*
Pregnancy Complications, Neoplastic / drug therapy*
Pyrimidines / adverse effects,  therapeutic use*
Remission Induction
Treatment Outcome
Withholding Treatment
Reg. No./Substance:
0/Antineoplastic Agents; 0/Piperazines; 0/Pyrimidines; 152459-95-5/imatinib

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Next Document:  Idiopathic hypereosinophilic syndrome: a case evolving in B-lymphoblastic lymphoma.